Publication: 3301

Publication: 3301

Biomarkers for Risk Stratification in Patients with Previously Untreated Follicular Lymphoma Receiving Anti-CD20-Based Biologic Therapy

PubMed

PMC

QxMD

DOI

Google Scholar

Citation:: Am J Surg Pathol vol 45 (3) 384-393

Year:: 2021
Type:: Manuscript
Funding:: NCTN
Endpoint:: Secondary-not-in-original
Analysis:: Meta-Analysis
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: pmc-release

Note:

Methodological:: No
Biospecimen:: Yes
SDC:: No
Book Volume:: 10

Parents:: 2393
Children:: None

Program:: TRP
Primary Committee:: Correl Sci NOS
Sec. Committees:

Pharmas:: from Celgene (CALGB 50803), GlaxoSmithKline (CALGB 50901)
Grants:: U10CA180821, U10CA180882, U24CA196171, UG1CA233180, UG1CA233329, UG1CA233339

Corr. Author:
Authors:: Aliyah R. Sohani Matthew J. Maurer Sharmila Giri Brandelyn Pitcher Amy Chadburn Jonathan W. Said Nancy L. Bartlett Myron S. Czuczman Peter Martin Cara A. Rosenbaum Sin-Ho Jung John P. Leonard Bruce D. Cheson Eric D. Hsi

Networks:: CAPITAL, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-MO011, LAPS-NY158, NY018

Study
Multiple Studies, or Legacy Studies in Alliance Study:: CALGB-50402, CALGB-50701, CALGB-50803, CALGB-50901
Phases:: 2

Keywords:: follicular lymphoma, BCL6, CD10, Ki67 proliferation index, prognostic biomarkers